Bio-Rad price target lowered to $320 from $340 at Wells Fargo

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Bio-Rad (BIO) to $320 from $340 and keeps an Equal Weight rating on the shares. The firm contends that it is “tough to argue for multiple expansion” after a Q4 miss and “weak” 2026 guidance, though it adds that the company’s portfolio assessment “could be interesting.”